Novo beats as Wegovy revenue doubles forecasts and 2026 sales, profit decline guidance narrows

 

Novo Nordisk beats Q1 estimates as Wegovy revenue doubles forecasts and 2026 sales, profit decline guidance narrows to 4%-12%

• Wegovy generated 2.26 billion kroner in Q1 revenue, about double analyst expectations.
• 2026 constant-currency sales and operating profit guidance now implies 4%-12% decline, versus 5%-13% previously.
• Wegovy reached about 200,000 weekly U.S. prescriptions by mid-April, Novo Nordisk's fastest GLP-1 launch ever.
• Q1 net income was $7.61 billion, with adjusted EPS of $1.04, beating expectations.
• Q1 revenue totaled $15.17 billion, above analyst sales consensus estimates.
• Quarterly adjusted operating profit topped expectations, prompting a slight increase in Novo Nordisk's full-year outlook.

https://finviz.com/quote?t=NVO&p=d